Martine Rothblatt, United Therapeutics CEO (Jack Plunkett/AP Images)
February 24, 2022 10:21 AM ESTUpdated 01:18 PM
FDA+

When a cit­i­zen pe­ti­tion works: FDA's re­view of Unit­ed Ther­a­peu­tic­s' PAH drug ex­tend­ed to May

Zachary Brennan

Senior Editor

Near­ly every time a bio­phar­ma com­pa­ny or its law firm files a cit­i­zen pe­ti­tion to de­lay a new or gener­ic drug’s ap­proval, the pe­ti­tion is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times